Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.92 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to $0.92 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.39, a N/A change, with the full-year FY2025 number at $0.39, up 108.9% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.92 for Q4 2025 at Soleno Therapeutics, up from $0.47 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.92 in Q4 2025 to a low of -$0.95 in Q1 2025.